AR038483A1 - Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides - Google Patents
Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoidesInfo
- Publication number
- AR038483A1 AR038483A1 ARP030100347A ARP030100347A AR038483A1 AR 038483 A1 AR038483 A1 AR 038483A1 AR P030100347 A ARP030100347 A AR P030100347A AR P030100347 A ARP030100347 A AR P030100347A AR 038483 A1 AR038483 A1 AR 038483A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylene
- cycloalkyl
- sor10
- so2r10
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000002947 alkylene group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 5
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 5
- 125000001931 aliphatic group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000006413 ring segment Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 3
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 2
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000005157 alkyl carboxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Chemical group 0.000 abstract 2
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 206010067013 Normal tension glaucoma Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 239000000604 anti-edema agent Substances 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 229940121376 cannabinoid receptor agonist Drugs 0.000 abstract 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000005243 carbonyl alkyl group Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000003001 depressive effect Effects 0.000 abstract 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical group FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 abstract 1
- 125000004990 dihydroxyalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 201000002978 low tension glaucoma Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 210000001328 optic nerve Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000050 smooth muscle relaxant Substances 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Derivados de quinazolinona de la fórmula (1); en donde: R1, R2, R3, R4, y R5 son independientemente hidrógeno; halógeno; alquilo C1-4; alquenilo C2-4; cicloalquilo C3-7; cicloalquiloC3-7-alquilo1-4; alcoxiloC1-4-alquiloC1-4; alquiloC1-4-carboxilo; hidroxialcoxiloC1-4-alquiloC1-4; hidroxilo; hidroxialquilo C1-4; fenilalquilo C1-4 que está opcionalmente sustituido por hidroxilo, alcoxilo C1-4, carboxilo, alcoxiloC1-4-carbonilalquiloC1-4, alcoxiloC1-4-carbonilo, ciano; -SO2R10; ciano; -SO2N(R10)R11; -S-R10; ó -SOR10; ó R1 y R2, ó R2 y R3 denotan, junto con los átomos de carbono con los que están unidos, un grupo carbocíclico aromático o alifático que tiene de 5 a 10 átomos de anillo, o un grupo heterocíclico aromático o alifático que tiene de 5 a átomos del anillo, de los cuales 1, 2, ó 3 son heteroátomos seleccionados a partir de nitrógeno, oxígeno, y azufre; R6 es -CH2-O-C(O)-N(R12)R13, -CH2-X-C(O)-R14; alquilo C1-4, ó hidroxialquilo C1-4; R7, R8, y R9 son independientemente alquilo C1-4; R10 y R11 son independientemente hidrógeno, alquilo C1-4; alquenilo C2-4; cicloalquilo C3-7; cicloalquiloC3-7-alquiloC1-4; alcoxiloC1-4-alquiloC1-4; alquiloC1-4-carboxilo; hidroxialquiloC1-4-alquiloC1-4; hidroxilo; hidroxialquilo C1-4; fenilalquilo C1-4 que está opcionalmente sustituido por hidroxilo, alcoxilo C1-4, carboxilo, alcoxiloC1-4-carbonilalquiloC1-4, alcoxiloC1-4-carbonilo, ciano; ciano; R10 y R11 forman juntos un grupo heterocíclico alifático que tiene de 5 a 10 átomos de anillo, de los cuales uno, dos, ó tres son heteroátomos seleccionados a partir de nitrógeno, oxígeno, y azufre; R12 y R13 son independientemente hidrógeno, alquilo C1-4, alquenilo C2-4, cicloalquilo C3-7, cicloalquiloC3-7-alquiloC1-4, alcoxiloC1-4-alquiloC1-4, hidroxialquiloC1-4-alquiloC1-4, hidroxialquilo C1-4, dihidroxialquilo C1-4, alcoxiloC1-4-carbonilalquiloC1-4, alcoxiloC1-4-carbonilo, ciano, -SO2R10; -SO2N(R10)R11, -S-R10, -SOR10, -alquilenoC1-4-SO2R10, -alquilenoC1-4-SOR10, alquilenoC1-4-NH-SO2R10, -alquilenoC1-4-CON(R10)R11, -CON(R10)R11, -alquilenoC1-4-C(O)OR10, fluoroalquilo, ó R12 y R13 forman un grupo heterocíclico alifático sustituido o insustituido que tiene de 5 a 10 átomos de anillo; R14 es NH, alquiloC1-4-NH-, alqueniloC2-4-NH-, cicloalquiloC3-7-NH-, cicloalquiloC3-7-alquiloC1-4-NH-, alcoxiloC1-4alquiloC1-4-NH-, hidroxialcoxiloC1-4-alquiloC1-4-NH-, hidroxialquiloC1-4-NH-, dihidroxialquiloC1-4-NH-, alcoxiloC1-4-carbonilalquiloC1-4-NH-, alcoxiloC1-4-carbonilo-NH-, -NH-alquilenoC1-4-CN, -NH-SO2R10, -NH-SO2N(R10)R11, -NH-alquilenoC1-4-S-R10, -NH-SOR10, -NH-alquilenoC1-4-SO2R10, -NH-alquilenoC1-4-SOR10, -NH-alquilenoC1-4-NH-SO2R10, -NH-alquileno-CON(R10)R11, -NH-CON(R10)R11, -NH-alquilenoC1-4-C(O)OR10, -NH-fluoroalquilo, o un grupo heterocíclico alifático sustituido o insustituido que tiene de 5 a 10 átomos del anillo; X es O ó CH2; con la condición de que, cuando R1 es halógeno, metilo, etilo, metoxilo, trifluorometilo, o hidrógeno, y R2, R3, R4 son hidrógeno, metilo, ó metoxilo, y R5 es hidrógeno o metilo, R12 no es hidrógeno, alquilo C2-4, alquenilo C2-4, hidroxialquilo C1-4, -alquilenoC1-4-SOR10, ni -alquilenoC1-4-SOR10; en forma de base libre o de sal de adición de ácido, procesos para su producción, su uso para la fabricación de medicamentos, y composiciones farmacéuticas que los comprenden. Los derivados de quinazolinona de fórmula (1) exhiben la actividad ligante al receptor (CB) canabinoide y son útiles como agonistas del receptor canabinoide para el tratamiento del dolor de varios orígenes o etiologías y como anti-inflamatorios y/o agentes anti-edémicos para el tratamiento de reacciones inflamatorias, enfermedades o infecciones, así como también para el tratamiento de la respuesta alérgica, el tratamiento de enfermedades psiquiátricas crónicas, tales como depresiones, desórdenes de depresiones y bipolar, estados psicóticos extremos. Además, el compuesto está indicado en atención al déficit de desórdenes de hiperactividad y otros desórdenes a la atención así como también a aquellos estados de comportamiento caracterizados por la renuncia social y para el tratamiento y prevención de enfermedades neurodegenerativas. Los derivados de quinazolinona de fórmula (1) son también útiles como relajantes del músculo liso y para el tratamiento de la espasticidad y el temblor, además, en el tratamiento de desórdenes oculares seleccionados del grupo que consiste de glaucoma, glaucoma de tensión normal y enfermedades neurodegenerativas de la retina y del nervio óptico.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0202755A GB0202755D0 (en) | 2002-02-06 | 2002-02-06 | Organic compounds |
| GB0213285A GB0213285D0 (en) | 2002-06-10 | 2002-06-10 | Organic compound |
| GB0221460A GB0221460D0 (en) | 2002-09-16 | 2002-09-16 | Organic compound |
| GB0221459A GB0221459D0 (en) | 2002-09-16 | 2002-09-16 | Organic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038483A1 true AR038483A1 (es) | 2005-01-19 |
Family
ID=27739227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100347A AR038483A1 (es) | 2002-02-06 | 2003-02-04 | Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20050085493A1 (es) |
| EP (2) | EP1472234B1 (es) |
| JP (2) | JP4428479B2 (es) |
| KR (1) | KR100954626B1 (es) |
| CN (1) | CN100579968C (es) |
| AR (1) | AR038483A1 (es) |
| AT (1) | ATE551329T1 (es) |
| AU (1) | AU2003210212A1 (es) |
| BR (1) | BR0307461A (es) |
| CA (1) | CA2471974C (es) |
| CO (1) | CO5601021A2 (es) |
| EC (1) | ECSP045219A (es) |
| ES (1) | ES2384967T3 (es) |
| MX (1) | MXPA04007641A (es) |
| MY (1) | MY143958A (es) |
| NO (1) | NO328305B1 (es) |
| NZ (1) | NZ571615A (es) |
| PE (1) | PE20030867A1 (es) |
| PL (1) | PL370657A1 (es) |
| TW (1) | TW200306839A (es) |
| WO (1) | WO2003066603A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000055153A1 (en) | 1999-03-17 | 2000-09-21 | Astrazeneca Ab | Amide derivatives |
| TW200306839A (en) | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| JP2007510649A (ja) | 2003-11-04 | 2007-04-26 | メルク エンド カムパニー インコーポレーテッド | 置換ナフチリジノン誘導体 |
| SE0303491D0 (sv) * | 2003-12-19 | 2003-12-19 | Astrazeneca Ab | New use VI |
| CN100506802C (zh) * | 2004-06-04 | 2009-07-01 | 中国科学院上海药物研究所 | 一类甲酰肽样受体-1调节剂、其制备方法和用途 |
| GB0413618D0 (en) * | 2004-06-17 | 2004-07-21 | Novartis Ag | Organic compounds |
| EP1904068A1 (en) * | 2005-07-11 | 2008-04-02 | N.V. Organon | Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| US20090209536A1 (en) * | 2007-06-17 | 2009-08-20 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| FR2944013B1 (fr) * | 2009-04-07 | 2011-07-15 | Sanofi Aventis | Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique. |
| EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
| CN104271579A (zh) | 2012-05-03 | 2015-01-07 | 诺华股份有限公司 | 作为生长素释放肽受体激动剂的2,7-二氮杂-螺[4,5]癸烷-7-基衍生物的l-苹果酸盐及其结晶 |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| CN106146414A (zh) * | 2016-07-07 | 2016-11-23 | 浙江大学 | 喹唑啉二酮类衍生物及其制备方法和用途 |
| CN106831502A (zh) * | 2017-03-13 | 2017-06-13 | 苏州市泽宸贸易有限公司 | 邻硝基苯磺酰氯、其合成方法及应用 |
| CN109796360B (zh) * | 2019-01-30 | 2022-03-18 | 上海阿拉丁生化科技股份有限公司 | 一种3-氨基-2-萘甲酸类化合物的制备工艺 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6200M (es) | 1967-04-18 | 1968-07-22 | ||
| DE1803210A1 (de) | 1968-10-16 | 1970-05-14 | Troponwerke Dinklage & Co | 2-Methyl-3-(3-[4-phenylpiperazinyl-(1)]-2-hydroxypropyl)-chinazolinon-(4) und Verfahren zu seiner Herstellung |
| JPS5657768A (en) * | 1979-10-18 | 1981-05-20 | Masayuki Ishikawa | Novel 4-quinazolone derivative substituted by aromatic residue at 3-position |
| NZ192392A (en) * | 1978-12-19 | 1983-02-15 | M Ishikawa | 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones |
| JPS57118570A (en) * | 1981-01-16 | 1982-07-23 | Masayuki Ishikawa | Novel 3-phenyl-4-quinazolone derivative |
| AU543928B2 (en) * | 1981-01-16 | 1985-05-09 | Masayuki Ishikawa | 4(311)-quinazolinone derivatives |
| EP0639986A1 (en) * | 1992-05-13 | 1995-03-01 | Alcon Laboratories, Inc. | Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents |
| US6017919A (en) | 1996-02-06 | 2000-01-25 | Japan Tobacco Inc. | Compounds and pharmaceutical use thereof |
| TW200306839A (en) | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
| SE0303491D0 (sv) | 2003-12-19 | 2003-12-19 | Astrazeneca Ab | New use VI |
| GB0413618D0 (en) * | 2004-06-17 | 2004-07-21 | Novartis Ag | Organic compounds |
-
2003
- 2003-01-30 TW TW092102105A patent/TW200306839A/zh unknown
- 2003-02-04 AR ARP030100347A patent/AR038483A1/es unknown
- 2003-02-04 PE PE2003000129A patent/PE20030867A1/es not_active Application Discontinuation
- 2003-02-05 CN CN03803448A patent/CN100579968C/zh not_active Expired - Fee Related
- 2003-02-05 PL PL03370657A patent/PL370657A1/xx unknown
- 2003-02-05 WO PCT/EP2003/001140 patent/WO2003066603A1/en not_active Ceased
- 2003-02-05 AT AT03737316T patent/ATE551329T1/de active
- 2003-02-05 JP JP2003565977A patent/JP4428479B2/ja not_active Expired - Fee Related
- 2003-02-05 MY MYPI20030387A patent/MY143958A/en unknown
- 2003-02-05 MX MXPA04007641A patent/MXPA04007641A/es unknown
- 2003-02-05 EP EP03737316A patent/EP1472234B1/en not_active Expired - Lifetime
- 2003-02-05 BR BR0307461-7A patent/BR0307461A/pt active Search and Examination
- 2003-02-05 NZ NZ571615A patent/NZ571615A/en not_active IP Right Cessation
- 2003-02-05 CA CA2471974A patent/CA2471974C/en not_active Expired - Fee Related
- 2003-02-05 EP EP10175740A patent/EP2319839A1/en not_active Withdrawn
- 2003-02-05 ES ES03737316T patent/ES2384967T3/es not_active Expired - Lifetime
- 2003-02-05 US US10/503,779 patent/US20050085493A1/en not_active Abandoned
- 2003-02-05 KR KR1020047012147A patent/KR100954626B1/ko not_active Expired - Fee Related
- 2003-02-05 AU AU2003210212A patent/AU2003210212A1/en not_active Abandoned
-
2004
- 2004-08-04 EC EC2004005219A patent/ECSP045219A/es unknown
- 2004-08-25 CO CO04083224A patent/CO5601021A2/es not_active Application Discontinuation
- 2004-08-27 NO NO20043580A patent/NO328305B1/no not_active IP Right Cessation
-
2007
- 2007-06-26 US US11/823,315 patent/US8552015B2/en not_active Expired - Fee Related
-
2009
- 2009-01-22 JP JP2009012064A patent/JP2009149658A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US8552015B2 (en) | 2013-10-08 |
| NO20043580D0 (no) | 2004-08-27 |
| CN1628104A (zh) | 2005-06-15 |
| EP1472234B1 (en) | 2012-03-28 |
| JP2009149658A (ja) | 2009-07-09 |
| BR0307461A (pt) | 2004-11-09 |
| NO328305B1 (no) | 2010-01-25 |
| ATE551329T1 (de) | 2012-04-15 |
| EP2319839A1 (en) | 2011-05-11 |
| US20050085493A1 (en) | 2005-04-21 |
| JP4428479B2 (ja) | 2010-03-10 |
| US20070265285A1 (en) | 2007-11-15 |
| KR100954626B1 (ko) | 2010-04-27 |
| CO5601021A2 (es) | 2006-01-31 |
| WO2003066603A1 (en) | 2003-08-14 |
| NZ571615A (en) | 2010-01-29 |
| AU2003210212A1 (en) | 2003-09-02 |
| CN100579968C (zh) | 2010-01-13 |
| TW200306839A (en) | 2003-12-01 |
| NO20043580L (no) | 2004-09-21 |
| CA2471974A1 (en) | 2003-08-14 |
| ES2384967T3 (es) | 2012-07-16 |
| ECSP045219A (es) | 2004-09-28 |
| EP1472234A1 (en) | 2004-11-03 |
| PL370657A1 (en) | 2005-05-30 |
| MY143958A (en) | 2011-07-29 |
| KR20040083501A (ko) | 2004-10-02 |
| PE20030867A1 (es) | 2003-12-04 |
| HK1079518A1 (zh) | 2006-04-07 |
| CA2471974C (en) | 2011-11-22 |
| MXPA04007641A (es) | 2004-11-10 |
| JP2005522439A (ja) | 2005-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038483A1 (es) | Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides | |
| CO5560573A2 (es) | Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20090556A1 (es) | DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION | |
| MX2024003721A (es) | Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| PE20090509A1 (es) | El uso de derivados de benzamida para el tratamiento de transtornos del snc | |
| AR063211A1 (es) | Derivados de 3-(piridin-3-il)acrilamida y 3-(piridin-3-il)propionamida, un metodo para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con el receptor vaniloide. | |
| AR048315A1 (es) | Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. | |
| AR035775A1 (es) | Compuestos derivados de quinazolin-4-ona y benzo[1,2,4]tiadiazina-1,1-dióxido, su uso, un proceso para su obtencion y composiciones farmaceuticas que los contienen | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| UY39559A (es) | Compuestos y su uso | |
| SE0202134D0 (sv) | Therapeutic agents | |
| AR060212A1 (es) | Compuestos de imidazo (1,2-b) piridacinas, procesos para su preparacion y de sus intermedios; usos de dichos compuestos; y composicion farmaceutica que los comprende | |
| NI200600257A (es) | Nuevos compuestos. | |
| AR074352A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica. | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| KR950701323A (ko) | 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives) | |
| PE20080378A1 (es) | Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| UY39517A (es) | Inhibidores de la btk | |
| SA523451700B1 (ar) | (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان | |
| ECSP088257A (es) | Derivados de amida | |
| NI200700311A (es) | Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3 | |
| TW200833697A (en) | Spiro-piperidine derivatives | |
| PE20240107A1 (es) | Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterociclicos farmacologicamente activos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |